Publications by authors named "Neil Conlon"

Claim this Profile
N
Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo.
Neil T Conlon, Sandra Roche, Amira F Mahdi, Alacoque Browne, Laura Breen

Transl Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Martina S J McDermott, Brigid C Browne, Neil T Conlon, Neil A O'Brien, Dennis J Slamon

Mol Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.
Sandra Roche, Patricia Gaule, Deirdre Winrow, Nupur Mukherjee, Fiona O'Neill, Neil T Conlon

PLoS One· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Derived from These Tumors.
Fiona O'Neill, Taylor-Jade Allen-Coyle, Sandra Roche, Justine Meiller, Neil T Conlon, Kevin Conlon

Life (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.
Taylor J Allen-Coyle, Jin Niu, Eva Welsch, Neil T Conlon, Weylon Garner

AAPS J· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview.
Riccardo Di Fiore, Sherif Suleiman, Francesca Pentimalli, Sharon A O'Toole, John J O'Leary, Neil T Conlon

Int J Mol Sci· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
Neil T Conlon, Jeffrey J Kooijman, Suzanne J C van Gerwen, Winfried R Mulder, Guido J R Zaman

Br J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions.
Riccardo Di Fiore, Sherif Suleiman, Bridget Ellul, Sharon A O'Toole, Charles Savona-Ventura, Neil T Conlon

Cancers (Basel)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients.
Sandra Roche, Fiona O'Neill, Jean Murphy, Niall Swan, Justine Meiller, Neil T Conlon, Kevin Conlon

Int J Mol Sci· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.
Alexandra Canonici, Alacoque L Browne, Mohamed F K Ibrahim, Kevin P Fanning, Sandra Roche, Neil T Conlon

Ther Adv Med Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Alexandra Canonici, Laura Ivers, Neil T Conlon, Kasper Pedersen, Nicola Gaynor

Invest New Drugs· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and -Mutated Breast Cancer.
Denis M Collins, Neil T Conlon, Srinivasaraghavan Kannan, Chandra S Verma, Lisa D Eli

Cancers (Basel)· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.
Martina S J McDermott, Neil Conlon, Brigid C Browne, Adam Szabo, Naoise C Synnott

Cancers (Basel)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts.
Orla Coleman, Michael Henry, Fiona O'Neill, Sandra Roche, Niall Swan, Neil T Conlon, Kevin C Conlon

Proteomes· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Alex J Eustace, Neil T Conlon, Martina S J McDermott, Brigid C Browne, Patrick O'Leary

BMC Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
Alexandra Canonici, Zulfiqar Qadir, Neil T Conlon, Denis M Collins, Neil A O'Brien

Invest New Drugs· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.
Tapesh Santra, Sandra Roche, Neil Conlon, Norma O'Donovan, John Crown

PLoS One· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Martina Sj McDermott, Brigid C Browne, Neil T Conlon, Neil A O'Brien, Dennis J Slamon

Mol Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis